A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

  • End date
    Jun 25, 2023
  • participants needed
  • sponsor
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Updated on 25 January 2021


This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.

Condition Advanced Renal Cancer
Treatment Sunitinib, Anlotinib, TQB2450
Clinical Study IdentifierNCT04523272
SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

\. Histopathologically confirmed renal clear cell cancer, including advanced renal cell carcinoma with clear cell components. 2. Has not receiving systemic therapy for local advanced/metastatic disease. 3. At least has one measurable lesion. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy 3 months. 5. Adequate laboratory indicators. 6. Agree to provide at least 5 slices tumor tissue samples for biomarker detection. 7. Serum or urine pregnancy tests are negative within 7 days before randomization; Men and women should agree to use effective contraception during the study period and after the end of the study period within 6 months. 8. Understood and signed an informed consent form

Exclusion Criteria

\. Has symptomatic central nervous system (CNS) disease and / or cancerous meningitis, pia mater disease. 2. Has received anti-angiogenesis targeted therapy or targeted PD-1 and PD-L1 immunotherapy. 3. Has active virus, bacteria, fungal infection; Cardiovascular and cerebrovascular diseases; Gastrointestinal abnormalities; Immunodeficiency; Bleeding risk; Lung disease; Neurological or psychiatric disorders. 4. Has participated in other clinical trials within 30 days before randomization. 5. Has received attenuated live vaccine within 28 days before randomization or planned to received attenuated live vaccine during the study period. 6. Pregnant or lactating women. 7. According to the judgement of the investigators, there are other factors that may lead to the termination of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note